BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 30442117)

  • 1. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
    Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H
    BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of circular RNA PUM1 inhibits clear cell renal cell carcinoma progression through the miR-340-5p/FABP7 axis.
    Zeng F; Luo L; Song M; Li D
    J Recept Signal Transduct Res; 2022 Apr; 42(2):141-150. PubMed ID: 33472512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
    White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
    Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analysis of fatty acid binding protein 7 and its effect on fatty acid of renal cell carcinoma cell lines.
    Takaoka N; Takayama T; Ozono S
    BMC Cancer; 2017 Mar; 17(1):192. PubMed ID: 28292269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FABP5 is correlated with poor prognosis and promotes tumour cell growth and metastasis in clear cell renal cell carcinoma.
    Wu G; Xu Y; Wang Q; Li J; Li L; Han C; Xia Q
    Eur J Pharmacol; 2019 Nov; 862():172637. PubMed ID: 31491402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of FABP's interactome and detecting new molecular targets in clear cell renal cell carcinoma.
    Wu G; Zhang Z; Tang Q; Liu L; Liu W; Li Q; Wang Q
    J Cell Physiol; 2020 Apr; 235(4):3776-3789. PubMed ID: 31602654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
    Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
    Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
    Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
    Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.
    Slipicevic A; Jørgensen K; Skrede M; Rosnes AK; Trøen G; Davidson B; Flørenes VA
    BMC Cancer; 2008 Sep; 8():276. PubMed ID: 18826602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
    Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
    Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
    Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
    Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
    Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
    Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.
    Liu Y; Cheng G; Song Z; Xu T; Ruan H; Cao Q; Wang K; Bao L; Liu J; Zhou L; Liu D; Yang H; Chen K; Zhang X
    Int J Oncol; 2019 Sep; 55(3):645-656. PubMed ID: 31364727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma.
    Xu GH; Lou N; Shi HC; Xu YC; Ruan HL; Xiao W; Liu L; Li X; Xiao HB; Qiu B; Bao L; Yuan CF; Zhou YL; Hu WJ; Chen K; Yang HM; Zhang XP
    BMC Cancer; 2018 Jan; 18(1):88. PubMed ID: 29357836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FABP5 regulates the proliferation of clear cell renal cell carcinoma cells via the PI3K/AKT signaling pathway.
    Lv Q; Wang G; Zhang Y; Han X; Li H; Le W; Zhang M; Ma C; Wang P; Ding Q
    Int J Oncol; 2019 Apr; 54(4):1221-1232. PubMed ID: 30968158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma.
    Yuan Y; Yang X; Li Y; Liu Q; Wu F; Qu H; Gao H; Ge J; Xu Y; Wang H; Wang Y; Zhao Z
    Pathol Res Pract; 2020 Nov; 216(11):153227. PubMed ID: 33027752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
    Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
    Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.